Imagin Medical Inc. (IMEXF) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 18, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerImagin Medical Inc. (IMEXF) trades at $0.0001. Imagin Medical Inc. is a surgical imaging company focused on developing the i/Blue Imaging System for bladder cancer detection. Sector: Healthcare.
Price as of · Last analyzed: Mar 18, 2026Analyst Coverage for IMEXF: IMEXF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Imagin Medical Inc. (IMEXF) Healthcare & Pipeline Overview
Imagin Medical Inc. is a surgical imaging company specializing in bladder cancer detection. It is developing the i/Blue Imaging System to enhance visualization for urologists during procedures. The company operates within the medical devices sector, focusing on improving diagnostic accuracy and treatment outcomes for bladder cancer patients.
What Is the Investment Thesis for IMEXF?
Imagin Medical Inc. presents a focused investment opportunity within the medical devices sector, specifically targeting bladder cancer diagnostics. The i/Blue Imaging System, currently under development, aims to improve the accuracy of bladder cancer detection during cystoscopy. Key value drivers include successful completion of clinical trials, regulatory approvals, and subsequent commercialization of the i/Blue system. Growth catalysts include potential partnerships with established medical device companies and expansion into new geographic markets. However, the company faces risks associated with regulatory hurdles, competition from existing imaging technologies, and the need for additional funding to support ongoing development and commercialization efforts. Investors should closely monitor the company's progress in clinical trials and its ability to secure strategic partnerships to de-risk the investment.
Based on FMP financials and quantitative analysis
IMEXF Key Highlights
Focus on bladder cancer, a prevalent and recurring disease, addresses a significant unmet need in urology.
- Development of the i/Blue Imaging System aims to enhance visualization during cystoscopy, potentially improving diagnostic accuracy.
- The company's strategic focus is on securing regulatory approvals and establishing commercial partnerships.
- Founded in 1986, Imagin Medical Inc. has a long-standing presence in the medical device industry.
- Headquartered in Vancouver, Canada, providing access to a strong talent pool and research ecosystem.
Who Are IMEXF's Competitors?
IMEXF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| BJDX Bluejay Diagnostics, Inc. | $0.76 | -9.01% | 30 5-pillar | |
| NVNO enVVeno Medical Corporation | $8.01 | -1.11% | $5.63M | 30 5-pillar |
| BDMD Baird Medical Investment Holdings Limited | $0.74 | -1.09% | $31.4M | — |
| SNWV SANUWAVE Health, Inc. | $4.70 | -2.49% | $41.5M | 36 5-pillar |
| SRTS Sensus Healthcare, Inc. | $2.92 | -2.01% | $48.1M | 31 5-pillar |
| HYPD Hyperion DeFi, Inc. | $3.89 | +4.29% | $56.5M | 36 5-pillar |
| LNSR LENSAR, Inc. | $6.67 | -1.19% | $81.9M | 45 5-pillar |
| APYX Apyx Medical Corporation | $2.60 | +1.96% | $107M | 33 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are IMEXF's Key Strengths?
Specialized focus on bladder cancer diagnostics.
- Innovative i/Blue Imaging System technology.
- Potential to improve diagnostic accuracy and patient outcomes.
- Experienced management team with expertise in medical devices.
What Are IMEXF's Weaknesses?
Limited financial resources.
- Dependence on successful development and commercialization of a single product.
- Lack of established market presence.
- OTC market listing may limit access to capital.
What Are the Key Risks for IMEXF?
Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Failure to obtain regulatory approvals for the i/Blue Imaging System.
- Competition from established medical device companies with greater resources.
- Delays in clinical trials or unexpected adverse events.
- Limited financial resources and dependence on external funding.
- The company's stock trades on the OTC market, which is subject to greater volatility and lower liquidity.
What Threats Does IMEXF Face?
- Competition from established medical device companies.
- Regulatory hurdles and delays.
- Technological obsolescence.
- Economic downturn affecting healthcare spending.
What Are IMEXF's Competitive Advantages?
- Proprietary i/Blue Imaging System technology.
- Focus on a specific niche market: bladder cancer diagnostics.
- Potential for strong relationships with urologists.
- Intellectual property protection through patents and trademarks.
What Does IMEXF Do?
Imagin Medical Inc., founded in 1986 and headquartered in Vancouver, Canada, operates as a surgical imaging company with a focus on bladder cancer. The company is dedicated to developing and commercializing innovative solutions that address the unmet needs of urologists in the detection and treatment of bladder cancer. Its primary product under development is the i/Blue Imaging System, designed to enhance the visualization of cancerous tissues during cystoscopy procedures. This system aims to improve the accuracy of bladder cancer detection, potentially leading to earlier diagnosis and more effective treatment strategies. Imagin Medical's focus on bladder cancer stems from the significant prevalence and recurrence rates associated with the disease. By providing urologists with advanced imaging tools, the company seeks to improve patient outcomes and reduce the overall burden of bladder cancer. The i/Blue Imaging System is intended to integrate seamlessly into existing clinical workflows, offering a user-friendly solution that enhances the capabilities of standard cystoscopy. The company's strategic focus is on securing regulatory approvals and establishing commercial partnerships to bring its technology to market and expand its reach within the urology community.
What Products and Services Does IMEXF Offer?
- Develop surgical imaging technology for bladder cancer detection.
- Focus on improving visualization during cystoscopy procedures.
- Create the i/Blue Imaging System to enhance diagnostic accuracy.
- Target the unmet needs of urologists in bladder cancer management.
- Seek regulatory approvals for their imaging system.
- Aim to commercialize their technology through partnerships and direct sales.
How Does IMEXF Make Money?
- Develop and commercialize the i/Blue Imaging System for bladder cancer detection.
- Generate revenue through sales of the i/Blue Imaging System to hospitals and clinics.
- Potentially generate revenue through service and maintenance contracts.
- Explore strategic partnerships with medical device companies for distribution and co-development.
What Industry Does IMEXF Operate In?
Imagin Medical Inc. operates within the medical devices industry, specifically targeting the bladder cancer diagnostics market. The industry is characterized by ongoing innovation in imaging technologies and minimally invasive procedures. The bladder cancer diagnostics market is driven by the increasing prevalence of the disease and the need for more accurate and earlier detection methods. Imagin Medical's i/Blue Imaging System aims to compete with existing cystoscopy techniques by offering enhanced visualization and improved diagnostic capabilities. Key competitors include companies offering alternative imaging modalities and diagnostic tools for bladder cancer.
Who Are IMEXF's Key Customers?
- Urologists who perform cystoscopy procedures.
- Hospitals and clinics that treat bladder cancer patients.
- Medical device distributors and partners.
- Patients undergoing bladder cancer screening and diagnosis.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Financial Health
Imagin Medical Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Key Financial Metrics
Return on equity for Imagin Medical Inc. stands at 20.0%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.01 means current liabilities exceed short-term assets, a liquidity point worth watching.
Company Profile
Imagin Medical Inc. operates in the Medical Devices industry within the Healthcare sector. It is headquartered in Vancouver, Canada.
IMEXF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
IMEXF Latest News
-
Stocks That Managed to Breach 52-Week Lows Friday
· Jul 26, 2019
IMEXF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for IMEXF.
Price Targets
Wall Street price target analysis for IMEXF.
IMEXF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for IMEXF; grades run from A+ (80-100) to F (below 30).
Leadership: Edward James Hutchens
CEO
Edward James Hutchens serves as the CEO of Imagin Medical Inc. His background includes extensive experience in the medical device industry, with a focus on surgical imaging and diagnostics. He has held leadership positions in various companies, overseeing product development, regulatory affairs, and commercialization strategies. Hutchens' expertise spans across multiple therapeutic areas, including urology and oncology. His educational background includes advanced degrees in engineering and business administration, providing him with a strong foundation for leading a technology-driven healthcare company.
Track Record: Under Edward James Hutchens' leadership, Imagin Medical Inc. has focused on advancing the development of the i/Blue Imaging System. Key milestones include securing funding for clinical trials, achieving regulatory designations, and establishing strategic partnerships. Hutchens has been instrumental in guiding the company's strategic direction and building a strong team to execute its vision. His focus on innovation and market needs has positioned Imagin Medical Inc. for potential growth in the bladder cancer diagnostics market.
IMEXF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Imagin Medical Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, and trading activity can be sporadic. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies are not subject to the same rigorous listing standards, leading to increased risk for investors. This tier often includes companies with limited operating history, distressed financials, or those that choose not to comply with higher reporting standards.
- OTC Tier: OTC Other
- Limited financial disclosure increases the risk of investing in IMEXF.
- Low trading volume and wide bid-ask spreads can lead to price volatility and difficulty in executing trades.
- The OTC Other tier designation indicates a higher level of risk compared to stocks listed on major exchanges.
- The company's dependence on the successful development and commercialization of a single product increases its vulnerability to setbacks.
- Potential for dilution through future equity offerings to fund ongoing operations.
- Verify the company's financial statements and SEC filings (if any).
- Assess the company's management team and their track record.
- Evaluate the competitive landscape and the company's market position.
- Determine the company's cash burn rate and runway.
- Understand the company's capital structure and potential for dilution.
- Consult with a qualified financial advisor.
- Independently verify all information provided by the company.
- The company has a long-standing presence since 1986.
- Focus on developing a specific medical device (i/Blue Imaging System) targeting a clear market need.
- CEO Edward James Hutchens has experience in the medical device industry.
- Headquartered in Vancouver, Canada, a recognized hub for medical technology innovation.
- Seeking regulatory approvals for their i/Blue Imaging System.
Imagin Medical Inc. Healthcare Stock: Key Questions Answered
What do analysts say about IMEXF stock?
As of 2026-03-18, formal analyst coverage of Imagin Medical Inc. (IMEXF) appears limited, likely due to its OTC listing and relatively small market capitalization. Key valuation metrics, such as P/E ratio, are currently not meaningful due to the company's lack of profitability.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited information available on OTC-listed companies.
- Financial data may not be readily accessible or independently verified.